In April 2026, Lipocine reported topline data from its Phase 3 placebo-controlled trial (N=90) of LPCN 1154, an oral brexanolone formulation for postpartum depression. The study did not meet its primary endpoint of HAM-D score reduction at hour 60 but demonstrated a differentiated safety profile with no treatment-related serious adverse events, excessive sedation or discontinuations and showed significant HAM-D score reductions in a post hoc psychiatric-history subgroup.

For the quarter ended March 31, unrestricted cash and marketable securities increased to $24.7 million from $14.9 million at December 31, 2025. The company reported a net loss of $3.7 million, or $0.52 per diluted share, versus a $1.9 million loss a year prior. TLANDO royalty revenue rose to $119,000, research and development expenses climbed to $2.8 million, and general and administrative expenses totaled $1.2 million.

Lipocine holds an exclusive U.S. and Canada license with Verity Pharma for TLANDO, its oral testosterone replacement therapy, and has additional license, supply and distribution agreements in Brazil (Aché), GCC countries (Pharmalink) and South Korea (SPC). The company continues to pursue partnerships to commercialize TLANDO in other territories.

Lipocine has applied for FDA breakthrough therapy and fast track designations for LPCN 1154 and awaits feedback. Management plans a full Phase 3 data analysis and presentations at medical conferences and is evaluating options including a validation study in patients with psychiatric histories, continued development of LPCN 1154, strategic partnerships, transactions and other pipeline opportunities.